The American pharmaceutical company Bristol Myers Squibb has announced its agreement to acquire oncology company Mirati Therapeutics for approximately 5.8 billion dollars (5.5 billion euros).
This acquisition aims to expand its product portfolio and gain access to drugs in clinical trial phases considered "promising."
The purchase of Mirati will allow Bristol Myers to incorporate the drug Krazati into its portfolio, which already has approval from U.S. regulatory authorities for the treatment of certain cases of lung cancer.
As part of the agreement, Bristol Myers will pay 58 dollars in cash per share of Mirati, in addition to granting Mirati shareholders rights valued at approximately 12 dollars, also in cash.
Bristol Myers executives emphasize that this operation will contribute to the growth of its oncology product line and strengthen its balance sheets in the coming years.
The transaction is subject to regulatory approval and is expected to close in the first half of 2024. This move is part of a trend in the pharmaceutical industry, where companies seek strategic agreements to offset the loss of exclusivity in drug distribution and face generic drug competition.
In response to this news, Bristol Myers experienced a 0.7% decline in its provisional trading on Wall Street, while Mirati suffered a 4.8% decrease. This agreement marks an important step in Bristol Myers' strategy to strengthen its presence in the field of oncology and diversify its product offerings.
Information from Cinco Días.
Receive all industry news in our weekly Newsletter Dialéctica Científica.